Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.

Primary objective: To evaluate the efficacy of fruquintinib combined with sintilimab versus TPC in the treatment of advanced endometrial cancer. Secondary objective: To evaluate other efficacy of fruquintinib combined with sintilimab versus TPC in the treatment of advanced endometrial cancer; To evaluate the safety and tolerability of fruquintinib combined with sintilimab versus TPC in the treatment of advanced endometrial cancer; To evaluate the pharmacokinetic (PK) characteristics of fruquintinib combined with sintilimab in patients with advanced endometrial cancer; To evaluate the effect of fruquintinib combined with sintilimab versus TPC in the treatment of advanced endometrial cancer on the quality of life score of patients. Exploratory objective: To evaluate the effect of biomarkers on efficacy.

Main purpose: To evaluate the safety and tolerability of surufatinib combined with carrelizumab, albumin-bound paclitaxel + gemcitabine (AG) as first-line treatment for metastatic pancreatic cancer To evaluate the efficacy of surufatinib combined with carrelizumab, AG and AG as first-line treatment for metastatic pancreatic cancer

To evaluate the safety and tolerability of fruquintinib combined with sintilimab in the dose escalation phase in patients with advanced solid tumors, observe possible dose-limiting toxicities, maximum tolerated doses, and/or determine the recommended Phase II dose and administration method for combination therapy. To evaluate the preliminary efficacy of fruquintinib combined with sintilimab in each cohort of patients with advanced solid tumors in the expansion phase of the study (except the endometrial cancer cohort) based on the tumor assessment data of the investigator (RECIST 1.1). To evaluate the tumor objective response rate (ORR) (RECIST 1.1) of fruquintinib combined with sintilimab in patients with advanced mismatch repair complete (pMMR) (confirmed by central laboratory testing) endometrial cancer who have disease progression after previous systemic treatment and are not suitable for radical surgery or radiotherapy (endometrial cancer cohort) based on the tumor assessment data of the independent imaging review committee (IRC). To evaluate the preliminary efficacy of the fruquintinib monotherapy group in patients with endometrial cancer based on the tumor assessment data of the investigator.